Diagnostic Usefulness of 18F-FDG PET/CT in Differentiated Thyroid Cancer Patients with Elevated Serum Thyroglobulin or Thyroglobulin Antibody Levels

Chalermrat Kaewput MD*, Pawana Pusuwan MD*

* Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Objective: To evaluate diagnostic accuracy of 18F-FDG PET/CT in detection of recurrence or metastases in differentiated thyroid cancer (DTC) patients with elevated stimulated thyroglobulin (sTg) or thyroglobulin antibody (TgAb) levels but negative 131I whole body scan (131I WBS).

Material and Method: Between January 2007 and December 2014, 38 18F-FDG PET/CT examinations in 38 DTC patients with elevated sTg levels (10 ng/ml or greater, n = 33) or elevated TgAb levels (40.0 IU/ml or greater, n = 5) but negative post-therapeutic 131I WBS or diagnostic 131I WBS were included. All patients underwent total thyroidectomy and radioiodine ablation. The 18F-FDG PET/CT findings were compared with histologic (n = 16) or clinical follow-up results based on serum Tg/TgAb levels or other imaging modalities. Duration of follow-up ranged from six months to seven years (median duration = 30 months).

Results: Thirty-two studies showed true positive lesions of local recurrence (n = 23, 60.5%), distant metastases (n = 2, 5.3%) and both local recurrence and distant metastases (n = 7, 18.4%). One study (2.6%) was considered as false positive lesions at cervical nodes, which was confirmed by histological result. Four studies (10.5%) were confirmed true negative results. A patient with no abnormal 18F-FDG avidity in subcentimeter cervical lymph nodes was clarified as false negative, as subsequent follow-up results showed slow rising of Tg levels with suggestion of cervical node metastases demonstrated by neck ultrasonography. Sensitivity, specificity, and accuracy of 18F-FDG PET/CT in the present study were 96.9%, 80%, and 94.7%, respectively. Additional information of previously undiagnosed lesions was found in seven patients i.e., meningioma and metastatic lesions in brain, bone, liver, muscle, and soft tissue.

Conclusion: The 18F-FDG PET/CT is useful for detection and localization of recurrence or metastases in DTC patients with negative 131I WBS but elevated sTg or TgAb levels. This technique also provides useful additional findings for appropriate management of these patients.

Keywords: Thyroid carcinoma, 18F-FDG PET/CT, Thyroglobulin, 131I whole body scan
Material and Method

Patients

Between January 2007 and December 2014, a total of 38 18F-FDG PET/CT examinations from 38 DTC patients (22 women, mean age 47.91±15.9 years, range 24 to 79 years) who had total thyroidectomy and at least once high dose radioiodine ablation for the treatment of DTC were examined. Patient with elevated Tg levels (10 ng/ml or greater, n = 33) after thyroid-stimulating hormone (TSH) stimulation (TSH greater than 30 mIU/l) or elevated TgAb levels (40.0 IU/ml or greater, n = 5) but negative post-therapeutic 131I WBS or diagnostic 131I WBS were included. The patients had previously received high dose I-131 treatment one to six times (median twice) for remnant tissue ablation or treatment of recurrent disease. Total therapeutic dose ranged from 150 to 1,000 mCi (median 300 mCi). The primary tumor histology type was papillary thyroid carcinoma in 37 cases. The remaining one case was follicular carcinoma. Patient characteristics are described in Table 1.

Radioiodine WBS

Radioiodine WBS was performed after thyroid hormone withdrawal for at least four weeks and strict low iodine diet for at least two weeks. Anterior and posterior whole-body images were obtained 48 to 72 hours after administration of 5 mCi of diagnostic 131I WBS or 150 to 200 mCi of post-therapeutic 131I WBS using a dual head gamma camera. Six diagnostic 131I WBS and 32 post-therapeutic 131I WBS were done.

Thyroglobulin and thyroglobulin antibody measurement

The TSH, Tg, and TgAb levels were measured at the day of the radioiodine administration. All patients were in TSH stimulation state with TSH greater than 30 mIU/l. Serum TSH, Tg, and TgAb levels were assayed on the cobas e411 platform (Roche Diagnostics GmbH, Manheim, Germany) which is based upon the electrochemiluminescence immunoassay. The cut-off of elevated Tg was above 10 ng/ml (n = 33). The cut-off of elevated TgAb was above 40 IU/ml (11). Thirty-three of 38 cases showed sTg above 10 ng/ml ranged from 11.1 to 6,055 ng/ml with normal TgAb level. Five patients showed high TgAb ranged from 1,905 to more than 4,000 IU/ml. Four patients of this group had sTg less than 1 ng/ml while the other one had sTg 4.4 ng/ml. Patients with elevated sTg level were divided into three groups as followed: group I: sTg ranged from 10 to 49.9 ng/ml (n = 10), group II: sTg ranged from 50 to 99.9 ng/ml (n = 7), and group III: sTg more than 100 ng/ml (n = 16).

18F-FDG PET/CT imaging protocol

Patients fasted for at least six hours before 18F-FDG PET/CT study. None of patients had blood glucose levels exceeding 150 mg/dl. The dose of 0.14 to 2.0 mCi/kg of 18F-FDG was injected intravenously and scanning began 60 minutes later using a Discovery PET/CT system (GE healthcare). Intravenous contrast agent was also used in all studies. Low-dose CT acquisition was performed first with 140 kV, 80 mA, 0.8 seconds per CT rotation, a pitch of 6 and a table speed of 22.5 mm/second. A PET emission scan was performed immediately after acquisition of CT without changing patient’s position. Five to seven bed positions were performed with an acquisition time of three minutes per bed from skull bed to mid-thigh. PETs images were reconstructed using an ordered-subset expectation maximization algorithm. CT data were used for attenuation correction. Studies were interpreted on a Xeleris workstation. PET/CT data were obtained within six months from the 131I WBS.

Image interpretation

PET/CT scans were interpreted independently by two experienced nuclear medicine physicians.
Any increased $^{18}$F-FDG uptake was compared with anatomical finding on CT. Focally increased $^{18}$F-FDG uptake with maximum uptake values (SUVmax) greater than 3.2 according to Hamed et al $(12)$ which did not correspond to normal structures was recorded as positive. Suggestive findings on CT were interpreted as negative, if they did not correspond to the area of abnormally increased $^{18}$F-FDG uptake. For each patient, the presence or absence, and localization of any recurrent lesions were determined. The SUVmax of the suspected lesions on PET/CT were also recorded.

**Recurrence evaluation**

PET/CT findings were compared with histology from reoperation or biopsy, other imaging modalities such as ultrasound, CT, and MRI, $^{131}$I WBS, and subsequent Tg and TgAb titers. The $^{18}$F-FDG PET/CT was classified as:

- True-positive: If positive findings on $^{18}$F-FDG PET/CT were confirmed by histopathologic results or correlative imaging modalities showed abnormal lesions with persistently abnormal follow-up Tg and TgAb titers, or the elevated Tg titer declined after empirical high dose radioiodine treatment.
- False-positive: If histopathologic results of suggestive lesions on $^{18}$F-FDG PET/CT were negative for malignancy or the lesions had resolved on subsequent follow-up imaging.
- True-negative: If no $^{18}$F-FDG uptake was found and patients had neither elevated Tg levels without any further treatment nor any evidence of recurrence in sub-sequent follow-up for at least 12 months.
- False-negative: If the findings on $^{18}$F-FDG PET/CT were negative and metastatic thyroid cancer was found on histopathologic results from reoperation or biopsy or disease progression was seen on other imaging modalities.

**Statistical analysis**

Results are presented as mean and SD of the mean. Overall sensitivity, specificity, and accuracy of $^{18}$F-FDG PET/CT were calculated. The sensitivities of PET/CT were further evaluated according to three groups of different Tg levels.

**Results**

**Positive $^{18}$F-FDG PET/CT**

Thirty-three of 38 studies showed positive findings. Thirty-two of 33 studies showed true positive (TP) lesions and were classified into three groups as followed: 1) local recurrence (LR) group showed positive lesions at thyroid bed (Fig. 1) or cervical nodes (n = 23, 60.5%), 2) distant metastatic group showed positive lesions at pulmonary and vertebrae (n = 2, 5.3%), and 3) LR with distant metastatic group showed positive lesions at thyroid bed or cervical nodes and outside neck regions i.e., brain, mediastinal nodes, pulmonary, muscle, liver, bone (n = 7, 18.4%). Six studies (15.8%) in group III were previously undiagnosed metastatic lesions at brain, pulmonary, muscle (bicep, trapezius, pectoralis minor, and gluteus maximus), liver, femur, and iliac bone which led to a change of therapy included external beam radiotherapy and surgical resection. Table 2 showed sites of positive lesions identified in PET/CT with each validated method. One study (2.6%) was considered as false positive lesion at cervical nodes (SUVmax range from 6.4 to 14.3) which were confirmed by negative malignancy on histological results from cervical node biopsy. Additional information of previously
undiagnosed benign lesion from PET/CT was found in one patient with meningioma.

**Negative 18F-FDG PET/CT**

Five of 38 studies showed no abnormal FDG uptake. Four of 38 studies (10.5%) were confirmed true negative results by gradual decreased Tg or TgAb levels without any further treatment for over 1 year. The remaining one patient showed no abnormal 18F-FDG avidity (SUVmax range from 1.3 to 1.9) in subcentimeter cervical lymph nodes which was clarified as false negative because of slow rising of Tg levels on subsequent follow-up and neck ultrasonography suggested cervical node metastases.

**Performance of PET/CT**

Sensitivity, specificity, and accuracy of 18F-FDG PET/CT in the present study were 96.9%, 80%, and 94.7%, respectively (Table 3). The sensitivity increased with high level of sTg. The sensitivity of PET/CT is 85.7% in group I and 100% in both group II and III.

**Table 2.** Validation of 18F-FDG PET/CT findings and location of recurrence or metastasis

<table>
<thead>
<tr>
<th>PET/CT Validation</th>
<th>Histopathology</th>
<th>Clinical follow-up</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>True positive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LR</td>
<td>13</td>
<td>10</td>
<td>23</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>LR with distant metastasis</td>
<td>2</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>False positive: LR</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>True negative</td>
<td>0</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>False negative</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>16</td>
<td>22</td>
<td>38</td>
</tr>
</tbody>
</table>

FDG = fluorodeoxyglucose; PET = positron emission tomography; CT = computed tomography; LR = local recurrence

**Table 3.** Overall performance of 18F-FDG PET/CT for detection of local recurrence or metastasis of DTC patients

<table>
<thead>
<tr>
<th>PET/CT Validation</th>
<th>Recurrence or metastasis Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
</tr>
<tr>
<td>Positive</td>
<td>32</td>
</tr>
<tr>
<td>Negative</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>33</td>
</tr>
</tbody>
</table>

Sensitivity = 96.9% Specificity = 80% Accuracy = 94.7%

DTC = differentiated thyroid cancer

**Discussion**

The 18F-FDG PET/CT is helpful for detecting recurrent or metastatic lesions in patients with increased sTg levels more than 10 ng/ml, and negative 131I WBS. The discordant between I-131 and FDG tumor uptake is attributed to differences in the degree of cellular differentiation. Poorly differentiated tumors showed high glucose uptake but lost their ability to concentrate iodine. "Flip-flop" phenomenon between I-131 and FDG uptake in metastatic thyroid cancer lesions was proposed by Feine.

Many studies showed range of sensitivity and specificity of 18F-FDG PET/CT for detecting local recurrence or metastasis in Tg-positive and 131I WBS-negative patients with TSH stimulation demonstrating a sensitivity and specificity of 80 to 95% and 70 to 85%, respectively. In present study showed comparable results with overall sensitivity 96.9% and specificity of 80%. In recent study of Na et al, 60 DTC patients with elevated sTg and negative 131I WBS showed sensitivity of 69.4% and specificity of 66.7% for detecting and localizing recurrent or metastatic tumor on 18F-FDG PET/CT. The present study showed higher sensitivity and specificity because we used higher cut-off level of sTg (10 ng/ml or greater vs. 2.0 ng/ml or greater in their study). In their study, the high sTg subgroup showed higher sensitivity than low sTg subgroup (sensitivity was 28.6%, 57.1%, 60%, and 78% for sTg 2 to 5, 5 to 10, 10 to 20, and more than 20 ng/ml, respectively), which are the same in the present study (sensitivity was 85.7% and 100% for sTg 10 to 49.9 and more than 50 ng/ml, respectively). Schlüter et al showed similar results that positive 18F-FDG PET/CT scans were achieved in 11% of DTC patients with sTg level 10 ng/ml or less and 50% with sTg levels 10 to 20 ng/ml and up to 93% at sTg greater than 100 ng/ml. The present study revealed three studies that clarified as true negative with sTg ranged 13.4 to 17.79 ng/ml. Because serum Tg level obtained after withdrawal of thyroid hormone therapy is strongly related to tumor mass. Patients with higher sTg level tend to have larger tumor mass and more aggressive disease which could be easily detected in 18F-FDG PET/CT. Hence, the usefulness of 18F-FDG PET/CT depends on sTg level.

During the initial years, a SUV of 2.5 was considered by many as a cut-off value to differentiate between benign and malignant disease. An abnormality with SUV more than 2.5 was used to consider malignant. However, learning with time, it is now not valid in the practice of PET. In countries with high
increased Tg levels\(^{12}\). Similar cut-off value is used by with sensitivity of 92% and specificity of 70% \(^{18}\). Takeda et al, showed that same SUVmax is the cut-off value to detect recurrence of localized non-small cell lung cancer with sensitivity of 100% and specificity of 96% \(^{19}\).

An important observation in the present study that in 23 of 32 TP cases were LR and 7 of 32 TP cases were LR with distant metastases. Most lesions were located in the neck region which is difficult for physical examination due to postoperative change. Neck ultrasonography is recommended to evaluate local recurrence at thyroid bed and neck node compartments performed at 6 to 12 months and then periodically, depending on the patient’s risk for recurrent disease and Tg status \(^{19}\). However, for lesions located in thyroidectomy bed, the distinction between recurrent tumors and non-recurrent benign lesions cannot be made on the basis of sonographic features. Fine-needle aspiration is helpful in determining the histologic nature of such lesions which is quite invasive \(^{20}\). The \(^{18}\)F-FDG PET/CT in the present study identified positive lesions outside neck which suggested distant metastases in nine studies, predominantly in the chest and bone. Six of nine studies were previously undiagnosed metastatic lesions at brain, pulmonary, muscle (bicep, trapezius, pectoralis minor, and gluteus maximus), liver, femur, and iliac bone which led to a change of therapy. Other various imaging modalities are also used to detect distant metastases in DTC patients with elevated sTg but negative \(^{131}\)I WBS and conventional imaging but pathologically increased Tg levels \(^{12}\). TgAb trend reflect change in mass of Tg-secreting thyroid tissue which is detected in approximately 20% of DTC patients and about 2-fold of normal upper limit as compared to the general population \(^{22}\). TgAb concentration serves as a surrogate post-operative DTC tumor marker. TgAb interfere with Tg immunometric assay (IMA) measurements which caused falsely low/undetectable Tg value. Current guidelines mandate that all specimens sent for Tg testing should have TgAb measurements added because the quantitative TgAb status determines risk for Tg assay interference \(^{23}\). In the present, four patients with elevated TgAb showed positive findings in PET/CT and were confirmed with metastatic cervical nodes by two histological results and two clinical follow-ups and all of them were clarified as TP studies. The remaining one case with high TgAb level of 1,417 IU/ml showed no abnormal uptake in PET/CT and after follow-up for over one year, TgAb level revealed gradual decreased to less than 50% of initial value without further treatment. This case was clarified as true negative. It is well documented that a rising TgAb trend, or de novo appearance of TgAb is commonly seen in the first few months (1 to 8 months) following surgery or radioiodine therapy in response to Tg antigen release by damaged cells. It must be distinguished from a sustained and progressive TgAb rise that may indicate of recurrence. In patients whose TgAb concentration fall to less than 50% of their initial value have a low risk of metastatic or recurrent tumor detected during the subsequent five years follow-up \(^{24}\). In the previous study of Na et al, three DTC patients with high TgAb (70.0 IU/ml or greater) with sTg less than 2 ng/ml showed positive findings in PET/CT which were confirmed with metastatic cervical lymph nodes by pathological results \(^{19}\). Kingpetch et al revealed sensitivity, specificity, and accuracy of \(^{18}\)F-FDG PET/CT in detection of recurrent or metastatic DTC patients with elevated serum TgAb levels but negative \(^{131}\)I WBS were 100%, 62.5%, and 72.7%, respectively \(^{25}\). Hereby, \(^{18}\)F-FDG PET/CT may be useful in detection of
recurrent or metastatic tumor in DTC patients with elevated TgAb and negative 131I WBS.

In the present study, treatment plans were changed in 18 patients (47.3%) after PET/CT scans performed. Ultrasonography-guided biopsy followed by operations of the lesions identified on PET/CT were carried out in 13 cases. In four cases, radiotherapy for extensive locoregional lesions and distant metastases (brain and mediastinal nodes) were performed. Radiofrequency ablation of cervical node recurrence in another patient was done.

Although the number of studied patients were rather small, the author’s results showed that 18F-FDG PET/CT may be useful for appropriate management of DTC patients with negative 131I WBS but elevated sTg level or TgAb level. Reimbursement of PET/CT for this group of patients should be considered in the future.

Conclusion

The 18F-FDG PET/CT may be a useful diagnostic tool in detection and localization of recurrence or metastases in DTC patients with elevated sTg level or TgAb level. Reimbursement of PET/CT for this group of patients should be considered in the future.

What is already known on this topic?

The 18F-FDG PET/CT is widely accepted to localize disease in DTC patients with high sTg levels (10 ng/ml or greater) and negative 131I WBS. Many studies showed range of sensitivity and specificity of 18F-FDG PET/CT for detecting local recurrence or metastasis in Tg-positive and 131I WBS-negative patients with TSH stimulation demonstrating a sensitivity and specificity of 80 to 95% and 70 to 85%, respectively.

What this study adds?

The present study showed advantage of 18F-FDG PET/CT in detection of previously undiagnosed metastatic lesions in DTC patients with high sTg level and negative 131I WBS at brain, pulmonary, muscle, liver, femur, and iliac bone which led to a change of therapy.

The authors hope that the present study will be recognize by the physicians to use 18F-FDG PET/CT for appropriate management of DTC patients with negative 131I WBS but elevated sTg or TgAb level. Reimbursement of PET/CT for this group of patients should be considered in the future.

Acknowledgement

This study was supported by the “Chalermprakiat Grant”, Faculty of Medicine Siriraj Hospital, Mahidol University. The authors would like to thank Julaporn Pooliam for her statistical support.

Potential conflicts of interest

None.

References


ความแม่นยำในการวินิจฉัยของการตรวจ $^{18}$F-FDG PET/CT ในผู้ป่วยมะเร็งไทรอยด์ชนิด differentiated ที่มีค่าไทโรบูลินหรือไทโรบูลินแอนติบอดีในเลือดสูงผิดปกติ

ผลการศึกษา: ผลการตรวจ $^{18}$F-FDG PET/CT พบว่าร้อยละ 60.5 มีการกลับเป็นซ้ำของโรคที่บริเวณคอ ร้อยละ 5.3 มีการแพร่กระจายของมะเร็งไปที่ส่วนอื่นนอกบริเวณคอ และร้อยละ 18.4 มีการกลับเป็นซ้ำของโรคที่บริเวณคอและมีการแพร่กระจายของมะเร็งไปที่ส่วนอื่น นอกจากนี้ยังมีข้อมูลที่ได้รับเพิ่มเติมจากการตรวจด้วย $^{18}$F-FDG PET/CT ในการรักษาในผู้ป่วยกลุ่มนี้ด้วย

สรุป: การตรวจด้วย $^{18}$F-FDG PET/CT มีประโยชน์ในการตรวจหา และระบุตำแหน่งของการกลับเป็นซ้ำหรือการแพร่กระจายของมะเร็งในผู้ป่วยมะเร็งไทรอยด์ชนิด differentiated ที่มีค่าไทโรบูลินหรือไทโรบูลินแอนติบอดีในเลือดสูงผิดปกติ แต่ไม่พบโรคจากผลภาพสแกนทั้งตัวด้วยไอโอดีน 131 นอกจากนี้ยังสามารถช่วยในการวินิจฉัยโรคอื่นเพิ่มเติมเพื่อประโยชน์ในการรักษาในผู้ป่วยกลุ่มนี้ด้วย